RARA CRAFT DATABASE for FDA Medical Devices
510(k)K180017

FDA DEVICE FACTS

MX40 Release C.01

Philips Medical Systems

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJuly 24, 2018PRODUCT CODEMHX

Indications for use

Intended Use Statement Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. Intended for monitoring and recording of, and to generate alarms for, multiple physiological parameters of adults and pediatrics in hospital environments and during transport inside hospitals. Intended for monitoring and recording of and to generate alarms for, multiple physiological parameters of adults and pediatrics in a hospital environment and during patient transport inside hospitals. Not intended for home use. Intended for use by health care professionals. Same Target Patient Population Adult and pediatric Same Users Trained health care professionals Same System Interface Connects to the Philips IntelliVue Information Center for transmission of patient parameters Same Care and Cleaning Available instructions in IFU Same Communication Smart Hopping 1.4GHz (CTS) Radio 802.11a/b/g/h Radio Short Range Radio 2.4 GHz Same Multi-Parameter patient monitoring ECG, Resp, SpO2, and NIBP (data acquisition for NIBP is not done by the MX40) Same Device Software, Device safety, environmental specifications, and all specifications of Unchanged, as previously submitted Masimo SET SpO2 measurement technology MX40 Release C.01 Summary of Non-clinical testing No performance standards have been issued under the authority of Section 514. The MX40 Release C.01 was tested in accordance with Philips verification and validation processes. Quality Assurance measures were applied to the system design and development, including:  Risk Analysis  Product Specifications  Design Reviews  Verification & Validations Summary of Clinical Testing Clinical Performance testing for MX40 Release C.01 was not performed, as there were no new clinical applications that had hazards or risk mitigations that required a clinical performance testing to support equivalence. Conclusions drawn from the Non-clinical and Clinical testing Verification, validation, and testing activities, where required to establish the performance, functionality, and reliability characteristics of the new device with respect to the predicate are performed. Testing involved system level tests, performance tests, and safety testing from hazard analysis. Pass/Fail criteria were based on the specifications cleared for the predicate device and test results showed substantial equivalence. The MX40 Release B.07 meets all defined reliability requirements and performance claims.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 27, 2026